Ekso Bionics Teams Up with Performance Contracting, Inc. for Innovative Testing Approach of EVO™ Technology
March 03 2021 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced that Performance Contracting, Inc.
(“PCI”), a leading U.S. specialty contractor, is the latest company
in the construction vertical to implement field testing of EVO™
exoskeleton vests. Over the course of a year, PCI employees in six
Bay Area counties have committed to testing EVO™ exoskeleton vests
for the Company’s continued product development and innovation.
“We are excited that PCI’s workforce will
benefit from our novel EVO technology,” commented Michael Pratt,
Vice President of Ekso Bionics. “Companies within the construction
vertical are starting to recognize that EVO provides meaningful
support for workers when performing routine and labor-intensive
tasks. We look forward to supporting our growing user base,
including PCI, with our unique solution and driving increased
adoption with our flexible subscription-based offering.”
EVO is the world’s most durable,
naturally-tracking, and assistive exoskeleton vest. The exoskeleton
offers unique benefits in the construction industry that aids
workers when performing strenuous tasks in order to reduce fatigue
and worker-related injuries while increasing productivity.
“Putting our people first has always been a key
differentiator at PCI,” said David Link, Regional Manager, Bay Area
of PCI. “With our team of over 6,300 skilled craft workers across
the United States, it is imperative for us to invest in both their
well-being and productivity to remain an industry leader. Ekso’s
EVO aligns with our most important core value of safety and
supports our performance-driven culture. We are eager to explore
this technology in the field with the goal of helping our employees
achieve their fullest potential.”
About Ekso Bionics®
Ekso Bionics® is a leading developer of
exoskeleton solutions that amplify human potential by supporting or
enhancing strength, endurance and mobility across medical and
industrial applications. Founded in 2005, the Company continues to
build upon its industry-leading expertise to design some of the
most cutting-edge, innovative wearable robots available on the
market. Ekso Bionics is the only exoskeleton company to offer
technologies that range from helping those with paralysis to stand
up and walk, to enhancing human capabilities on job sites across
the globe. The Company is headquartered in the San Francisco Bay
Area and is listed on the Nasdaq Capital Market under the symbol
“EKSO.” For more information, visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
About Performance Contracting,
Inc.
With over 40 offices nationwide, Performance
Contracting Inc. (“PCI”) provides quality services and products to
the industrial, commercial, and non-residential markets—from
complex interior build-out services to large-scale insulation
systems and scaffolding. As a result of world-class construction
and a people-first focus, this employee-owned company is
consistently ranked among the Top 10 Specialty Contractors in the
United States. For more information, visit
https://www.performancecontracting.com/.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the potential benefits, performance,
durability and effectiveness of the Company’s products and systems,
including EVO, or their impact on productivity or fatigue
reduction, and the assumptions underlying such statements. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company’s current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the ongoing COVID-19 pandemic and its
impact on the Company’s financial condition and business, the
highly competitive markets in which the Company’s products are
sold, the new and unproven nature of the market for the Company’s
products, the long and variable sales cycles for the Company’s
products, the factors outside the Company’s control that affect the
international sales of its products, the costs related to and
impacts of potential failure of the Company to obtain or maintain
protection for the Company's intellectual property rights, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, and risks related to product
liability, recall and warranty claims. These and other factors are
identified and described in more detail in the Company’s filings
with the U.S. Securities and Exchange Commission. To learn more
about Ekso Bionics please visit the Company’s website at
www.eksobionics.com or follow @EksoBionics on Twitter. The Company
does not undertake to update these forward-looking statements.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024